N-Boc-[1-(氨甲基)丙基]胺 | 732219-83-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-Boc-[1-(氨甲基)丙基]胺
• 英文名称: tert-Butyl (1-aminobutan-2-yl)carbamate
• 英文别名: tert-butyl N-(1-aminobutan-2-yl)carbamate
• CAS: 732219-83-9
• 化学式: C₉H₂₀N₂O₂
• 分子量: 188.27
• InChiKey: KGJCYTMWAXWVOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,5-difluorobenzyl)-2-mercaptoimidazole-5-carboxylic acid 、 N-Boc-[1-(氨甲基)丙基]胺 、 甲酸 生成 N-(2-aminobutyl)-3-[(3,5-difluorophenyl)methyl]-2-sulfanylidene-1H-imidazole-4-carboxamide
  参考文献：
  名称：

  FINKELSTEIN, JOSEPH A.;FRUSE, LAWRENCE L.;LEONARD, THOMAS B.

  摘要：

  DOI：

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• [EN] BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE PI3K/MTOR ET PROCÉDÉS DE LEURS UTILISATION ET FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012071519A1

  公开（公告）日：2012-05-31

  The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  该发明涉及公式I的化合物10以及其药用可接受的盐或溶剂化合物，以及制备和使用这些化合物的方法。
• BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS
  申请人：Jia Zhaozhong J.

  公开号：US20120142671A1

  公开（公告）日：2012-06-07

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

  本发明涉及公式I的化合物及其药学上可接受的盐、酯和前药，这些化合物是Syk激酶的抑制剂。本发明还涉及用于制备这些化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病，如非霍奇金淋巴瘤的方法。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：Rice Kenneth D.

  公开号：US20140080810A1

  公开（公告）日：2014-03-20

  The invention is directed to Compounds of Formula I: (I) and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens.

  本发明涉及化合物I式：（I）及其药学上可接受的盐或溶剂化物，以及使用该化合物进行治疗的方法，筛选抑制剂化合物的方法和确定治疗方案的方法。
• Dopamine-beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0284375A1

  公开（公告）日：1988-09-28

  Compounds of formula (I) : in which X is H, F, Cl, Br, I, C₁₋₄alkyl, CN, NO₂, SO₂NH₂, COOH, CHO, C₁₋₄alkoxy, CH₂OH, CF₃, SO₂CH₃, SO₂CF₃ or CO₂CaH2a+1 wherein a is 1-5; n is 0-5; R is hydrogen or C₁₋₄alkyl, and R¹ is OH or NHC₁₋₄alkylNH₂; and pharmaceutically acceptable salts or hydrates thereof, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy as dopamine-β-hydroxylase inhibitors.

  式 (I) ： 其中 X 是 H、F、Cl、Br、I、C₁₋₄烷基、CN、NO₂、SO₂NH₂、COOH、CHO、C₁₋₄烷氧基、CH₂OH、CF₃、SO₂CH₃、SO₂CF₃或 CO₂CaH2a+1 其中 a 是 1-5；n 为 0-5；R 为氢或 C₁₋₄ 烷基，R¹ 为 OH 或 NHC₁₋₄ 烷基 NH₂；及其药学上可接受的盐或水合物、制备工艺、用于制备它们的中间体、含有它们的药物组合物以及它们作为多巴胺-β-羟化酶抑制剂在治疗中的用途。